Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status ≤ 2 (according to WHO criteria)~* Patient with early invasive breast cancer histologically confirmed stage I to IIIA)~* Positive or negative lymph node involvement~* Positive or negative Hormonal Receptors (Estrogens and/or Progesterone),~* Equivocal HER2 status (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤ HER2 gene number copy \< 6) as assessed on surgical specimen~* Adequate Hematological, Hepatic, Renal and Cardiac Functions~* Patient potentially eligible for an anti-HER2 therapy~* Patient eligible to receive an adjuvant therapy~* Signed Informed Consent~* Patient with social insurance.~Exclusion Criteria:~* Non-measurable tumor~* Unknown Hormonal Receptors~* Unknown node involvement~* Positive or negative HER2 status (Score 0, 1 or 3 IHC, or Negative or positive ISH)~* Disease stage ≥IIIB~* Patient not able to follow the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of PAM 50 test in Her2 equivocal breast cancer patient (Type: EXPERIMENTAL): Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test).

Based on this trial design, predict the completion outcome and termination type (if applicable).